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Summary
When testing for superiority in a parallel-group setting with a continuous outcome,
adjusting for covariates (e.g., baseline measurements) is usually recommended, in
order to reduce bias and increase power. For this purpose, the analysis of covariance
(ANCOVA) is frequently used, and recently, several exact and approximate sample
size calculation procedures have been proposed.However, in case of multiple covari-
ates, the planningmight pose some practical challenges and surprising pitfalls, which
have not been recognized so far. Moreover, since a considerable number of parame-
ters have to be specified in advance, the risk of making erroneous initial assumptions,
leading to substantially over- or underpowered studies, is increased. Therefore, we
propose a method, which allows for re-estimating the sample size at a prespecified
time point during the course of the trial. Extensive simulations for a broad range
of settings, including unbalanced designs, confirm that the proposed method pro-
vides reliable results in many practically relevant situations. An advantage of the
reassessment procedure is that it does not require unblinding of the data. In order
to facilitate the application of the proposed method, we provide some R code and
discuss a real-life data example.
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1 INTRODUCTION
In clinical trials with a parallel-group design, the main interest is often focused on the question whether a particular intervention
is more efficacious than a competitor or placebo. For continuous outcomes, the alternative hypothesis of superiority can be
examined by using a one-sided two-sample t test. However, it is well known that in general, adjusting for one or several covari-
ates may increase the power of the test and reduce the bias of the effect estimator.1 For example, it is sensible to include at least
one baseline measurement of the outcome as a covariate in the statistical model.2 The importance of an adjustment for baseline
measurements has been highlighted and discussed extensively in a recent regulatory guideline.3 We would like to emphasize
that settings where more than one random covariate should be accounted for, are supposed to be frequently encountered in
applied research. For example, in order to assess the efficacy of a treatment in spinal cord injury patients with respect to bladder
function4, it may be sensible to adjust not only for the baseline measurement of the outcome (e.g., detrusor pressure), but
also for another baseline variable, which is presumably correlated with the outcome (e.g., cystometric volume). In a recently
published clinical trial from stroke research, the NIHSS score at 24 hours after the intervention was considered as the primary
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outcome, and group means were adjusted for NIHSS at baseline5. However, incorporating, for example, the age of the patient
as a further random covariate into the model would have been an appealing alternative way of analyzing the data from that trial.
The analysis of covariance (ANCOVA) is a well-established statistical method, which allows for covariate adjustment.
ANCOVA tests have been used to assess treatment effects in clinical trials from virtually every medical research area (e.g.,
neurology6,7, gynaecology8, geriatrics9). Applying an appropriate method for sample size calculation plays a key role in the
planning phase of any interventional study. It has to be ensured that the target power is indeed achieved or, on the other hand,
that patients are not unnecessarily exposed to potentially harmful treatments.10,11 However, a recent systematic review indicates
that even if the ANCOVA was used, sample sizes were not calculated appropriately.12 This might reflect the lack of awareness
that the topic of sample size calculation in ANCOVA models has recently been addressed in several publications.Tereenstra et
al. considered an ANCOVA model with a single baseline measurement of the outcome in the context of a cluster-randomized
trial design.13 Sample size calculation in the classical parallel two-group setting was discussed in a very concise and readily
understandable way by Borm et al.14 They exploited some analogies between the t-test and the ANCOVA test statistics, in
order to get two approximate formulas, which were based on the classical normal approximation and the Guenther-Schouten
adjustment, respectively.15,16 Recently, however, this approach has been criticized by Shieh, who derived an exact method for
calculating power and sample sizes for an ANCOVA model with multiple random covariates.17 Tang proposed another two
methods and compared them to existing approaches in the context of designs with and without stratification.18 Apart from these
papers, the seminal publication of Frison and Pocock2 as well as a recent approach, which is based on sample size calculation
methods for multivariate outcomes19, should be mentioned as references for the special case of an adjustment for several
repeated measurements of the outcome variable.
With an increasing number of covariates, the amount of uncertainty in sample size calculation increases, too. In the ANCOVA
model, additionally to the variance of the outcome and the effect size, one has to provide “good guesses” of the covariance
matrix of the covariates as well as the correlations between the outcome and the covariates. If these hypothesized values, which
can be either based on previous studies or subject matter expertise, are not close to the true values, the resulting actual power and
calculated sample sizes might be inaccurate. Therefore, it would be sensible to recalculate the sample size at some pre-specified
time point during the course of the study. This can be regarded as a special case of an adaptive design, although it should be
noted that only the nuisance parameters, but not the effect sizes are re-estimated in the interim analysis.20,21 A crucial issue
with that sort of recalculation methods is whether or not blinding of the data is required. If unblinding is needed for the interim
analysis, a data monitoring committee has to be established, in order to preserve the integrity of the study. Since this is resource-
consuming, an appealing alternative would be to use a sample size reassessment method, which does not require unblinding of
the data. For an overview of existing methods, we refer to the comprehensive reviews of Proschan22 and Friede and Kieser.23
In the present paper, we propose a blinded sample size recalculation procedure for an ANCOVA model with multiple random
covariates, extending the methods that have been examined by Friede and Kieser for the case of one single random covariate.24
Our manuscript is organized as follows. In Section 2, we introduce some notation as well as sample size formulas for the
fixed design, and describe the main steps of our proposed recalculation method in detail. Moreover, we also place emphasis on
practical aspects by discussing some potential problems, which might arise when (re-)calculating sample sizes for a multiple
ANCOVA model, and suggest appropriate remedies. To our knowledge, these surprising difficulties have not been addressed in
the literature so far. Then, in Section 3, we investigate the performance of both fixed sample size calculation formulas and our
proposed recalculation procedure with respect to type I error rates, empirical power and average as well as maximum sample
sizes in an extensive simulation study, covering a broad range of parameter configurations. We demonstrate the application of
our proposed method to real-life data in Section 4. We conclude with a discussion of the advantages and limitations as well
as some ideas for future research. In the online supplement, we provide the R code that can be used for applying our proposed
method in real-life settings, as well as the simulation results for the fixed sample size calculation settings.
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2 SAMPLE SIZE FORMULAS, BLINDED SAMPLE SIZE RECALCULATION
PROCEDURE, AND PRACTICAL CONSIDERATIONS
2.1 Approximate formulas for the fixed sample size setting
Let (푌푖푗 ,퐙
′
퐢퐣
) be independent, following a multivariate (푐 + 1)-dimensional normal distribution with mean vector (휇푖,흁
′
푍
)′ and
covariance matrix 훴, 1 ≤ 푗 ≤ 푛푖, 푖 ∈ {1, 2}. The adjusted means 휇1, 휇2 may differ, whereas the covariate means and the
covariance matrix are assumed to be equal across the groups. The covariance matrix 훴 of the joint distribution of the outcome
and the covariates can be conveniently expressed as
훴 ∶=
[
휎2
푌
흈′
푌 푍
흈푌푍 훴푍
]
,
where 휎2
푌
and 훴푍 denote the variance of the outcome and the covariance matrix of the covariates, respectively, and 흈푌 푍 repre-
sents a 푐-dimensional vector, which contains the covariances between the outcome and each covariate.
Consider testing for superiority of group 1 over group 2 in terms of the group means, that is, 퐻0 ∶ 휇1 ≤ 휇2 vs. 퐻1 ∶ 휇1 > 휇2.
In this setting, it is well known that under퐻0,
푇 ∶=
휇̂1 − 휇̂2
휎̂
(1)
follows the central 푡 distribution with 푛1+푛2−2− 푐 degrees of freedom, where 휇̂푖 denotes the estimated adjusted mean in group
푖, 푖 ∈ {1, 2}, and
휎̂ ∶= 푉̂ 푎푟(휇̂1 − 휇̂2) =
(
1
푛1
+
1
푛2
+푄(푍)
)
푛1 + 푛2 − 2
푛1 + 푛2 − 2 − 푐
휎̂2
푌
(1 − 푅̂2). (2)
Thereby,푄(푍) ∶= 퐙̄′
푑
(
(푛1 + 푛2 − 2)훴̂푍
)−1
퐙̄푑 , where 퐙̄푑 ∶= (푍̄1
(1)
−푍̄2
(1)
,… , 푍̄1
(푐)
−푍̄2
(푐)
)′. Moreover, 푅̂2 denotes the square
of the estimated pooledmultiple correlation coefficient between the outcome and the covariates, that is, 푅̂2 ∶= 흈̂′
푌 푍
훴̂−1
푍
흈̂푌 푍∕휎̂
2
푌
,
where 휎̂2
푌
, 흈̂푌 푍 and 훴̂푍 denote the pooled estimators of 휎
2
푌
, 흈푌 푍 and 훴푍 , respectively. Exact unconditional power for the
ANCOVA 퐹 test was derived by Shieh.17 Following this approach, exact sample sizes for a specified power value can be
obtained iteratively. However, in order to facilitate sample size calculations by avoiding numerical or iterative computations,
several approximations have been proposed. In the sequel,푁 = 푛1 + 푛2 denotes the total sample size, 훾 = 푛2∕푛1 the allocation
ratio, 훼 and 훽 are the type I and II error levels, and 푧푝 denotes the 푝-quantile of the standard normal distribution. Let Δ be
the stipulated difference of the adjusted means (i.e., the clinically relevant difference). Then, by generalizing the approximate
sample size calculation methods discussed by Friede and Kieser24, the following formulas are proposed.
1. Basic approximate formula:
푁퐴 =
(훾 + 1)2
훾
(푧1−훼∕2 + 푧1−훽)
2휎2
푌
(1 −푅2)
Δ2
, (3)
2. Guenther-Schouten-like adjustment (GS):
푁퐺푆 = 푁퐴 +
푧2
1−훼∕2
2
. (4)
3. Degrees-of-freedom adjustment (DF):
푁퐷퐹 = 푁퐴
푁퐴 − 2
푁퐴 − 2 − 푐
. (5)
4. Combined Guenther-Schouten and degrees-of-freedom adjustment (GS + DF):
푁퐺푆,퐷퐹 = 푁퐷퐹 +
푧2
1−훼∕2
2
. (6)
It should be noted that the sample size formulas correspond to a one-sided level 훼∕2 test, as recommended by guide-
lines regarding hypothesis testing in a superiority setting.10 A formal justification of (3) as well as some heuristic arguments
concerning (5) and (6) are provided in the appendix.
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2.2 A method for blinded interim sample size reassessment by re-estimating nuisance parameters
We propose the following procedure for blinded sample size recalculation:
1. Calculate the initial sample size푁푖푛푖푡, using the degrees-of-freedom adjustment approach (5).
2. As soon as data from푁휏 ∶= 휏푁푖푛푖푡 patients is available, 휏 > 0, estimate the residual variance 휎̂
2
휏
of the linear regression
model
푌푖푗 = 훽0 +
푐∑
푘=1
푍(푘)푖푗 훽푘 + 휖푖푗 , 푖 ∈ {1, 2}, 푗 ∈ {1, 2,… , 푛푖},
that is, the residual variance based on a regression model for the pooled sample. This approach has been proposed for the
case of one random covariate by Friede and Kieser24. The main idea is that unblinding is not required here, because the
residual variance based on the data from the pooled sample can be calculated without knowing the group indicators. Of
course, the estimators will be biased, but evidence from the simple ANCOVA suggests that the impact of that bias on the
expected sample size is small.25
3. Recalculate the sample size by using the Guenther-Schouten approach, that is,
푁̂푟푒푐 =
(훾 + 1)2
훾
(푧1−훼∕2 + 푧1−훽)
2휎̂휏
Δ2
+
푧2
1−훼∕2
2
.
At this point, one may ask why the Guenther-Schouten adjustment is used instead of the degrees-of-freedom adjustment.
The reason is that the residual variance of a regression model with outcome 푌 and explanatory variables 푍1,… , 푍푐 is
equal to 휎2
푌
(1−푅2)휅, where 휅 = (푁−2)∕(푁−2−푐). Hence, the residual variance estimator from the previous step already
accounts for the degrees of freedom. Consequently, the degrees-of-freedom adjustment lacks any underlying rationale in
this context and could even lead to an over-adjustment.
4. The final sample size is determined according to the formula
푁̂푓푖푛푎푙 = min{max(푁휏 , 푁̂푟푒푐), 푁푏표푢푛푑},
where 푁푏표푢푛푑 = 푘 ⋅ 푁푖푛푖푡, 푘 ≥ 1, and 푘 is determined by the available resources and the time horizon for the trial. As a
consequence, the final sample size is contained in the interval [푁휏 , 푘 ⋅ 푁푖푛푖푡]. Thus, we allow for either in- or decreasing
the initially planned sample size at the interim recalculation, yet making sure that the final sample size cannot grow “too
large” compared to 푁푖푛푖푡. The latter restriction is sensible from a statistical point of view, especially when 푁휏 is quite
small, because substantial uncertainty in estimating the residual variance might lead to an excessive inflation of the final
sample size. Moreover, from a practical point of view, financial and human resources are limited. Actually, bounding the
final sample size, for example, at the fourfold of푁푖푛푖푡 is a quite ambitious choice, and even a doubled sample size might
already present a challenge in implementation.
Needless to say that the sample sizes obtained in each step are rounded to the smallest integer that is equal to or greater than
the calculated value. In addition, depending on the allocation ratio 훾 , another adjustment has to be done. For example, if we
consider a balanced design (i.e., 훾 = 1) and the total final sample size 푁̂푓푖푛푎푙 is odd, we must add 1 in order to get an even number.
2.3 Some practical considerations
In the fixed sample size setting as well as in the first step of our proposed sample size reassessment procedure, several quantities
have to be provided by subject-matter experts or have to be extracted from previous studies. When calculating approximate
sample sizes for a 푡 test without any covariates, only 휎2
푌
and Δ are required. Now, the approximate formula (3) in the multiple
ANCOVA setting differs from the 푡 test formula by the factor (1 − 푅2). Especially for 푐 = 1, this is a well-known rule-of-
thumb: At first, one calculates the sample size as if a 푡 test was used in the final analysis. In a second step, the sample size is
being multiplied with one minus the squared correlation between the outcome and the covariate. Formula (3) shows that this
calculation rule can be extended to the multiple ANCOVA case, with the squared correlation replaced by the squared multiple
correlation coefficient 푅2. However, in practice, it might be difficult to obtain this factor directly. Therefore, we would like to
briefly discuss the following approaches:
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1. Iterative calculation: Apply the following formula to calculate 푅2 iteratively, based on an푅2 value from a reduced model
and a partial correlation coefficient26:
푅2
푌 ;푍1 ,…,푍푐
= 푅2
푌 ;푍1,…,푍푐−1
+ (1 −푅2
푌 ;푍1,…,푍푐−1
)휌2
(푌푍푐 )|(푍1 ,…,푍푐−1),
where 푅2 and 휌2 denote the squared multiple and partial correlation coefficients, respectively. For example, in case of
푐 = 2, this formula reduces to
푅2
푌 ;푍1,푍2
= 휌2
푌 푍1
+ (1 − 휌2
푌 푍1
)휌2
(푌 푍2)|푍1 .
Some caution is required here: Formally, the partial correlation coefficient 휌(푌 푍2)|푍1 is defined as the Pearson correlation
based on the elements of the covariance matrix of the conditional distribution of (푌 ,푍2), given푍1 = 푧1 for some 푧1 ∈ ℝ.
However, that covariance matrix does not depend on the particular choice of 푧1.
26 Hence, one could basically use any
estimated correlation between 푌 and 푍2 from a previous study as a “good guess” of that partial correlation coefficient.
2. Definition of 푅2: Taking into account that 푅2 = (흈′
푌 푍
훴푍흈푌 푍∕휎
2
푌
), 푅2 is calculated by specifying the (푐 + 1)(푐 + 2)∕2
nuisance parameters which uniquely define the covariance matrix of the covariates as well as the correlations between the
covariates and the outcome and the variance of the outcome. This approach might well be feasible in practice, because it
is moreorless straightforward to extract these correlations and variances from previous studies or infer them from expert
opinion. However, apart from the considerable increase in the number of parameters for growing 푐, some configurations
of individual parameters might yield an 푅2 value that exceeds 1, which would in turn lead to negative sample sizes. For
example, consider a scenario with 푐 = 2 covariates, and let 휎2
푌
= 휎2
푍1
= 휎2
푍2
= 1, 퐶표푣(푌 ,푍1) = 퐶표푣(푌 ,푍2) = 0.7 and
휌푍1,푍2 = 퐶표푣(푍1, 푍2) = −0.3. Then, 푅
2 = 1.4 > 1. Interestingly, this cannot be explained by merely referring to the
fact that there might be some logical inconsistencies (observe that 퐶표푣(푌 ,푍1) and 퐶표푣(푌 ,푍2) are both positive, whereas
퐶표푣(푍1, 푍2) is negative). If we slightly change the setting and let 퐶표푣(푌 ,푍1) = 퐶표푣(푌 ,푍2) = 0.5, we get푅
2 = 0.714 <
1. Therefore, everything should work well in this case, although there still might be some logical inconsistencies due to
the different signs of the covariances. This surprising behaviour has not been noted in the literature so far, although that
sort of difficulties is likely to arise in practice.
In order to solve this problem, one should check whether the joint covariance matrix 훴 is positive semidefinite, because
this would imply 푅2 ∈ [0, 1]. For the special case of 훴 having a compound symmetry structure (i.e., 휎2 ∶= 휎2
푌
= 휎2
푍1
=
… = 휎2
푍푐
, 휌 ∶= 휌푌 푍1 = … = 휌푌 푍푐 = 휌푍푖푍푗 for all 푖 ≠ 푗), we can even characterize the positive semidefinite matrices 훴:
The eigenvalues of 훴 are 휆1 = 휎
2(1 + 푐휌) with multiplicity 1 and 휆2 = 휎
2(1 − 휌) with multiplicity 푐. Thus, 훴 is positive
semidefinite if and only if 휌 ≥ −1∕푐. In more general cases, one has to do an eigenanalysis after having specified the
nuisance parameters. In order to facilitate the use of the proposed sample size formulas for applied researchers, the R code
provided in the online supplement automatically checks for positive semidefiniteness and returns a warning message if
this condition is not met.
3 SIMULATION STUDY
In order to evaluate the performance of the aforementioned approximate fixed sample size formulas and our proposed sam-
ple size recalculation procedure, we conducted an extensive simulation study. At first, we investigated the case of 푐 = 2
covariates. The observations and covariates were drawn from a trivariate normal distribution with mean vectors (휇푖, 0, 0)
′,
푖 ∈ {1, 2}, where 휇2 = 0 and 휇1 = Δ ∈ {0.25, 0.5, 0.75}. Further, we assumed a compound symmetry structure for the
covariance matrix of the covariates 훴푍 , that is 훴푍 = 휎
2
푍
퐼2 + 휌푍(퐽2 − 퐼2), where 퐼2 and 퐽2 denote the 2-dimensional
identity matrix and the matrix containing all 1’s, respectively. We set 휎2
푌
= 휎2
푍
= 1 and considered all combinations of
흈푌 퐙 ∈ {(0.25, 0.25)
′, (0.5, 0.5)′, (0.75, 0.75)′, (0.25, 0.5)′, (0.25, 0.75)′, (0.5, 0.75)′} and 휌푍 ∈ {0.25, 0.5, 0.75}. Observe that
we thus cover a broad range of 푅2 values, since these configurations yield 푅2 ∈ {0.071, 0.083, 0.100, 0.250, 0.267, 0.286,
0.333, 0.400, 0.567, 0.571, 0.583, 0.643, 0.667, 0.750, 0.786, 0.900}. Regarding the group sizes, we considered a balanced
design (i.e., 훾 = 푛2∕푛1 = 1). Additionally, we repeated the simulations for all scenarios where 휌푍 = 0.5 employing a 1:2
allocation ratio (i.e., 훾 = 2). To our knowledge, only 1:1 allocation has been considered in the literature so far, despite the
practical relevance of unequal allocation ratios. For example, in a study where the investigators want to show superiority of
a new drug over the standard treatment, but the new drug is supposed to carry a high risk of severe adverse events, unequal
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allocation may be an attractive option. Moreover, in order to investigate whether the performance of our proposed method
changes substantially with increasing 푐, we conducted simulations for 푐 = 3 covariates, too. We set 휎2
푍1
= 휎2
푍2
= 휎2
푍3
= 1,
퐶표푣(푍1, 푍2) = 퐶표푣(푍2, 푍3) = 0.5 and 퐶표푣(푍1, 푍3) = 0.25. All other specifications were the same as described above, with
퐶표푣(푌 ,푍3) = 0.5 as the third coordinate of 흈푌 푍 . For each scenario, we conducted 푛푠푖푚 = 1, 000, 000 simulation runs, which
resulted in an estimated standard error of 0.0004 for the empirical power (1 − 훽 = 0.80) and 0.0002 for the type I error rate
(훼∕2 = 0.025), respectively.
At first, we report the results concerning the performance of the four fixed sample size procedures in terms of sample sizes
and power, in comparison with the results from the exact approach proposed by Shieh.17 The basic approximate formula (3)
performed well only in large samples, yet showing considerable deviations from the respective exact values in small samples.
Proceeding with formulas (4)–(6), the performance was gradually getting better, with the sample sizes based on the combined
Guenther-Schouten and degrees-of-freedom adjustment (6) being equal to the exact sample sizes in most scenarios. As an
alternative, however, the degrees-of-freedom adjustment (5) also yielded good approximations, unless the sample sizes were
very small. Apart from that, it should be noted that the sample sizes were larger for unbalanced scenarios (i.e., 훾 = 2) than in
balanced settings, regardless whether the exact or one of the approximate methods was used. All results can be found in full
detail in Tables 1–5 in the online supplement.
For the simulations regarding our proposed sample size recalculation procedure, the parameter 휏, which specifies the time
point of the interim reassessment, was set to 0.5. The final total sample size was bounded at the fourfold of the initially planned
sample size 푁푖푛푖푡 (i.e., 푘 = 4). Final average sample sizes and empirical power were compared to the corresponding values
that were obtained by using the exact fixed sample size calculation approach proposed by Shieh.17 Firstly, in balanced designs
with 푐 = 2 covariates, the pre-specified level of 훼∕2 = 0.025 was well maintained, with a median type I error rate of 0.02509
(range 0.02462−0.02554). The median simulated power of the recalculation procedure was 0.80028 (range 0.78731−0.85603).
The exact sample sizes corresponding to the minimum and maximum simulated power values are 푁 = 18 and 푁 = 12,
respectively, indicating that the method might have a somewhat suboptimal performance for very small total sample sizes. This
corresponds to a trend towards increased deviations from the target power for large hypothesized effects Δ (Figure 1 ). At this
point, however, the question arises if it is sensible to consider a scenario with extremely small sample sizes at all, because in the
interim reassessment, a regression model with 3 parameters is fitted to data from푁∕2 ∈ {6, 9} subjects.
Anyway, apart from these few instances, the proposed sample size recalculation procedure performs very well, with the
empirical power close to the target level. For example, if only those scenarios with a total exact sample size≥ 30 (i.e., 15 subjects
per group) are considered, the empirical power of the recalculation procedure ranges from 0.79850 to 0.80272. Moreover,
observe that the simulated power for the recalculation procedure is most of the time closer to the target level of 0.8 than the exact
power value, even though all parameters were correctly specified. With respect to the sample sizes, the recalculation procedure
yields expected final sample sizes which exceed the exact values by 6.1 subjects on average. Depending on the particular setting,
the difference can be up to 7.1. Similar discrepancies have been found for the ANCOVA model with one covariate, as reported
by Friede and Kieser.24 So, even in the case of 푐 = 2 covariates, the overall “price” one has to pay for the increased flexibility of
the recalculation procedure is small, thus rendering the proposed method useful for practical applications. However, one has to
keep in mind that especially in small samples, the maximum final sample size resulting from the recalculation procedure could
exceed the initially planned sample size considerably.
Basically, compared to the balanced settings, the performance for 훾 = 2 is similar, if not even slightly better. The empirical
type I error rates are close to the nominal level (median 0.02506, range 0.02456− 0.02558). The maximum deviations from the
target are even smaller than in the balanced settings, and the empirical power always lies above 0.8 now (median empirical power
0.80287, range 0.80041− 0.82300). Especially for Δ = 0.75, the exact power substantially exceeds the target level, whereas the
deviation of the power of the recalculation method is much lower (Figure 2 ). The average difference between the expected final
sample sizes and the corresponding fixed exact sample sizes is 6.0 (range 4.4−7.4), which is similar to the balanced setting, too.
In case of balanced designs with 푐 = 3 covariates, the proposed sample size reassessment procedure yields empirical power
values which are consistently smaller than 0.8. While the method still performs well for Δ ∈ {0.25, 0.5}, there is some power
loss for Δ = 0.75 in most cases (e.g., empirical power of 0.77424 for 흈푌 푍 = (0.75, 0.75, 0.5)
′; Figure 3 ). However, the type I
error rates are still close to the pre-specified level (median 0.02501, range 0.02472 − 0.02527).
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FIGURE 1 Empirical power of the proposed sample size recalculation procedure vs. exact power in the fixed sample size design
with correct specification of nuisance parameters, and target power. Cov 1 to 3 indicate different compound symmetry structures
of the covariance matrix of the covariates (휌푍 = 푖 × 0.25, 푖 ∈ {1, 2, 3}), and the labels on the x axis denote the correlations
between the outcome and covariate 푗, 푗 ∈ {1, 2}: 푐1 = (0.25, 0.25), 푐2 = (0.5, 0.5), 푐3 = (0.75, 0.75), 푐4 = (0.25, 0.5),
푐5 = (0.25, 0.75), 푐6 = (0.5, 0.75).
So far, we have only considered somewhat idealistic settings, assuming that the nuisance parameterswere correctly specified in
advance. In these scenarios, where a fixed sample size calculation approach is supposed to yield reliable results, the recalculation
procedure performed equally well and was even slightly superior in some cases. Additionally, we shall consider two settings
now, where the advantages of the increased flexibility due to the interim reassessment becomes even more obvious, because the
covariance matrix Σ푍 of the covariates was misspecified. On the one hand, we assumed that initially, 휌푍 was set to 0.75, but
the true value was 0.5. On the other hand, instead of 휌푍 = 0.75, we used 휌푍 = 0.25 for the initial sample size calculation. It
can be seen in Figure 4 that our proposed recalculation procedure outperformed the fixed sample size calculation method in
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FIGURE 2 Empirical power of the proposed sample size recalculation procedure vs. exact power in the fixed sample size
design with correct specification of nuisance parameters, and target power, assuming a compound symmetry structure of the
covariance matrix of the covariates, where 휎푍 = 1 and 휌푍 = 0.5, and unbalanced group sizes, 푛2 = 2푛1. The labels on the x axis
denote the correlations between the outcome and covariate 푗, 푗 ∈ {1, 2}: 푐1 = (0.25, 0.25), 푐2 = (0.5, 0.5), 푐3 = (0.75, 0.75),
푐4 = (0.25, 0.5), 푐5 = (0.25, 0.75), 푐6 = (0.5, 0.75)
all scenarios. The latter deviated substantially from the target power of 80 percent in some settings. Although the sample size
reassessment procedure was somewhat underpowered for covariance scenario 푐6 (i.e., moderate to strong correlations between
the outcomes and the covariates, which in turn translates to small sample sizes) and misspecification scenario 2 (i.e., assuming
that 휌푍 was equal to 0.25 instead of 0.75), it is still preferable over the fixed sample size calculation method, which totally
failed in that scenario. Moreover, similarly to all previously discussed settings, our proposed method again keeps the 훼 level
well (median 0.02498, range 0.02466–0.02568).
4 APPLICATION TO A REAL-LIFE SETTING
In order to illustrate the application of our proposed sample size recalculation procedure, we use data from the SIESTA (Sedation
vs. Intubation for Endovascular Stroke TreAtment) trial. In this monocentric randomized parallel-group trial, the main aim was
to assess if conscious sedation is superior to general anesthesia for early neurological improvement among patients receiving
stroke thrombectomy. The change from baseline of the National Institutes of Health Stroke Scale (NIHSS) 24 hours after the
interventionwas considered as the primary outcome,whichwas compared between the two groupswhile adjusting for theNIHSS
at baseline. For further details, we shall refer to the original publication of the results.5 Regarding sample size calculation, the
investigators report that the estimated variances, which were obtained from previous studies, showed considerable variation.
Even worse, an estimate of the correlation between the outcome and the NIHSS at baseline was not available at all. Therefore,
it was decided to conduct a preliminary sample size calculation with the t test formula, which yielded a total sample size
푁 = 100, assuming equal group allocation. When data of 75 patients was available (i.e., 휏 = 0.75), a pre-planned blinded
sample size recalculation was carried out, using the method proposed by Friede & Kieser.24 Further details are provided in the
study protocol.27
Clearly, this is a case where an interim sample size reassessment is more appropriate than calculating sample sizes in advance
and keeping them fixed throughout the conduct of the study. The latter approach would have to rely on a somewhat arbitrary
initial guess of the correlation and on a variance estimate which is subject to considerable uncertainty. So, the method employed
in the SIESTA study was definitely a good choice. Nevertheless, we shall examine whether the final sample size would have
substantially changed if multiple covariates had been considered. At this point, we would like to mention that the primary
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FIGURE 3 Empirical power of the proposed sample size recalculation procedure vs. exact power in the fixed sample size
design with correct specification of nuisance parameters, and target power, assuming an ANCOVA model with 푐 = 3 covariates,
a compound symmetry structure of the covariance matrix of the covariates, where 휎푍 = 1 and 휌푍 = 0.5, and balanced group
sizes, 푛1 = 푛2. The labels on the x axis denote the correlations between the outcome and covariate 푗, 푗 ∈ {1, 2, 3}: 푐1 =
(0.25, 0.25, 0.5), 푐2 = (0.5, 0.5, 0.5), 푐3 = (0.75, 0.75, 0.5), 푐4 = (0.25, 0.5, 0.5), 푐5 = (0.25, 0.75, 0.5), 푐6 = (0.5, 0.75, 0.5)
outcome as well as some of the covariates, which will be considered below, are ordinally scaled variables. However, for the
classical ANCOVA as well as for our proposed method to be applied, normally distributed variables are required. Since there is
some evidence that type I error rates and power are not substantially affected by applying the classical ANCOVA to ordinally
scaled outcomes and baseline measurements thereof28, it is appropriate to use the data for illustrating the application of our
proposed sample size recalculationmethod. Nevertheless, we would like to emphasize that the resulting effect sizes (i.e., adjusted
mean differences) should be interpreted with caution if the outcome and / or the covariates are ordinally scaled.
In the sequel, we perform several sample size recalculations, based on the data that was available at the time of the interim
analysis, assuming a group allocation ratio 훾 = 1 and a clinically relevant difference Δ = 4. We set 훼 = 0.05 and 1 − 훽 = 0.9.
These specifications correspond to the setup described in the study protocol; by contrast, however, we do not impose an upper
bound on the final sample size, because this would complicate the assessment of potential differences between the respective
models. For sample size recalculation, we conducted steps 2 and 3 from Section 2.2. At first, we reproduced the sample size
reassessment that had been actually carried out in the study, assuming an ANCOVA model with one single covariate, namely
NIHSS at baseline. The estimated residual variance and final sample size were 휎̂휏 = 99.35 and 푁̂푟푒푐 = 264, respectively. Next,
we added the age of the patients (in years) as a second covariate. Using this model, both values slightly decreased (휎̂휏 = 96.99,
푁̂푟푒푐 = 258). As an alternative, we considered replacing age by the degree of recanalization, as quantified by the Thrombolysis
in cerebral infarction (TICI) scale. So, again, we had a scenario with 푐 = 2 covariates, namely NIHSS at baseline and TICI.
Obviously, the inclusion of TICI led to a substantial decrease of the final sample size down to 푁̂푟푒푐 = 214 (휎̂휏 = 80.42). Finally,
we added the door-to-intervention time (in seconds) to the model. Taking NIHSS at baseline, TICI and door-to-intervention
time as covariates, we got 휎̂휏 = 77.43 and 푁̂푟푒푐 = 206, respectively.
Summing up, we would like to emphasize three important points. Firstly, we have seen that in all scenarios, the recalculated
sample sizes substantially exceeded the initially planned sample size푁 = 100. So, obviously, if the reassessment had not been
applied, the study would have been considerably underpowered. Secondly, careful thoughts about the associations between the
outcome and potential covariates are required in the planning phase. In the example, the inclusion of TICI led to a considerable
decrease of the final sample size, whereas there was hardly any use in adding age to the model. Thirdly, although our example
of course only provides limited evidence, it seems as if increasing the number of covariates beyond 푐 = 2 would not lead to
further substantial improvements, which is consistent with findings in a similar context (repeated measures).2
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FIGURE 4 Empirical power of the proposed sample size recalculation procedure vs. exact power in the fixed sample size design
in case of 푐 = 2 covariates, assuming 휎푍 = 1, and balanced group sizes, 푛1 = 푛2. The labels on the x axis denote the correlations
between the outcome and covariate 푗, 푗 ∈ {1, 2}: 푐1 = (0.25, 0.25), 푐2 = (0.5, 0.5), 푐3 = (0.75, 0.75), 푐4 = (0.25, 0.5),
푐5 = (0.25, 0.75), 푐6 = (0.5, 0.75). Misspecification 1: 휌푍 = 0.75 was assumed for sample size planning, although the true
correlation was 0.5. Misspecification 2: 휌푍 = 0.25 was assumed for sample size planning, although the true correlation was
0.75.
5 DISCUSSION AND CONCLUSIONS
Although some work concerning exact and approximate sample size calculation in the context of an ANCOVA model with
multiple covariates has been published recently, there is currently no method available, which allows for blinded sample size
recalculation in that setting. We have proposed such a method here, based on the approach suggested by Friede and Kieser24 for
the situation of one single covariate. At the time point of the blinded interim reassessment, the residual variance is estimated
based on the pooled interim data, and the final sample size is recalculated accordingly. The results of our extensive simulation
study indicate that even if all parameters are correctly specified, the performance of the blinded recalculation method is close
to the exact results for models with 2 random covariates and for most scenarios with 3 covariates, except in cases where the
required sample size is very small (i.e., Δ = 0.75). In more realistic scenarios, where initial misspecifications of a nuisance
parameter are present, our proposed method is clearly superior to the fixed approach. Apart from that, regardless whether a
fixed sample size calculation formula or a recalculation method is employed, caution is needed when initially specifying the
values of the nuisance parameters, in order to prevent the sample sizes provided by the formula from being negative. This
surprising discovery is important and has to be taken into consideration when applying the aforementioned methods in real-life
settings (e.g., by checking for positive semidefiniteness of the joint covariance matrix).
The sample size calculation formulas, which are used in our proposed procedure, have been derived assuming a multivariate
normal distribution of the covariates and the outcome. However, in applied research, this assumption is frequently violated. The
outcome and / or the covariates may not even be continuous (e.g., ordinal scores like the modified Rankin Scale, the Hamilton
Depression Score, etc.). We have already touched this issue briefly in Section 4, providing some explanation how the ANCOVA
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results can be used and interpreted, though. In such instances, however, using nonparametric ANCOVA methods29 would be an
attractive alternative with respect to the interpretation and the robustness of the results. Nevertheless, for parallel-group com-
parisons, sample size calculation methods are only available for the unadjusted Wilcoxon-Mann-Whitney test30,31. Therefore,
investigating sample size (re-)calculation procedures for nonparametric ANCOVA is a promising goal of future research.
Basically, our proposed recalculation method can be applied to ANCOVA models with an arbitrary number of covariates.
However, we restricted to a thorough examination of various settings with 푐 = 2 and 푐 = 3 as well as balanced and unbalanced
scenarios. Evidence from repeated measures models indicates that if the number of baseline visits is increased, there is always
a reduction of the required sample size (i.e., a gain in power). However, the magnitude of that reduction decreases considerably
with a growing number of baseline visits.2 In our simulation study, we also noticed that already for 푐 = 3 the reduction in
sample sizes compared to a similar scenario for 푐 = 2 was not larger than 10 in most cases. Moreover, especially in small to
moderate samples, multicollinearity issues are more likely to occur with an increasing number of covariates. Therefore, all
in all, we recommend including at most 3 covariates into the model, thus maintaining a balance between gains in power and
feasibility in practical applications.
It should generally be noted that any blinded reassessment procedure cannot correct for misspecified effect sizes. For this
purpose, an adaptive design with unblinded interim analysis would be an appealing alternative. However, such a method has
the disadvantage that unblinding and, thus, establishing an independent data monitoring committee are required. Furthermore,
regulatory guidelines prefer blinded sample size reassessment due to avoiding bias.32,33
To conclude, firstly, we have assessed the performance of several approximate fixed sample size calculation approaches in
terms of sample sizes and power. According to the results of the simulation studies, the proposed adjustments which take the
number of covariates into account are easy to apply and can be safely used in practice. Moreover, most importantly, we have
proposed a blinded sample size recalculation method for an ANCOVA model with multiple random covariates and showed by
extensive simulations that it maintains the pre-specified type I error level and power very well in models with 2 or 3 covariates,
except for very small sample sizes. In case of initial misspecifications, our proposed method outperforms the fixed sample size
calculation approach. Thus, applied researchers now have a procedure at hand, which is easy to use and increases the robustness
of sample size calculation while at the same time keeping the treatment allocation blinded.
APPENDIX
Derivation of the basic approximate sample size formula (3) in Section 2
At first, we rewrite the test statistic 푇 defined in (1) as
푇 =
Δ̂√
(푛−1
1
+ 푛−1
2
+ 푄̂푍 )휅푄̂푌 푍
,
where 푄̂푍 ∶= 퐙̄
′
푑
(
(푛1 + 푛2 − 2)훴̂푍
)−1
퐙̄푑 , Δ̂ ∶= 휇̂1−휇̂2, 휅 ∶= (푛1+푛2−2)∕(푛1+푛2−2−푐), 푄̂푌 푍 ∶= 휎̂
2
푌
(1−휎̂−2
푌
흈̂′
푌 푍
Σ̂−1
푍
흈̂푌 푍).
Next, we apply the normal approximation of the 푡 distribution. Using 푛2 = 훾푛1 and doing some algebra yields
Δ̂2
(푛−1
1
+ 푛−1
2
+ 푄̂푍)휅푄̂푌 푍
≈ (푧1−훼∕2 + 푧1−훽)
2
⇔
Δ̂2
(훾푛1)
−1(훾 + 1 + 훾푛1푄̂푍)
≈ (푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍
⇔ 훾푛1Δ̂
2 ≈ (푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍(훾 + 1 + 훾푛1푄̂푍)
⇔ 푛1(1 − (푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍푄̂푍∕Δ̂
2) ≈ (푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍(훾 + 1)∕(훾Δ̂
2). (7)
Now, observe that 푄̂푍 is most likely close to 0: 퐙̄푑 is supposed to be small for reasonable sample sizes, since the covariate
means of the populations are equal to 흁푍 for both groups. Moreover, the elements of the inverse of 훴̂푍 will be small, too, unless
the variances are close to 0, or the covariates exhibit strong linear dependencies. As either scenario would lead to potentially
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serious problems regarding inference, these cases can be excluded. Moreover, observe that the factor (푛1 + 푛2 − 2)
−1 leads to a
further deflation of the quantity 푄̂푍 . Hence, it might be appropriate to drop the term (푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍푄̂푍∕Δ̂
2. Thus, we
can further simplify (7) to
푛1 ≈
(푧1−훼∕2 + 푧1−훽)
2휅푄̂푌 푍(훾 + 1)
훾Δ̂2
.
Finally, observe that 휅 ≈ 1 for reasonably large sample sizes, and that 푄̂푌 푍 = 휎̂
2
푌
(1 − 휎̂−2
푌
흈̂′
푌 푍
Σ̂−1
푍
흈̂푌 푍), according to the
definition of 푄̂푌 푍 . This completes the derivation of (3).
Some remarks regarding formulas (5) and (6)
The approximate formulas (5) and (6) can be motivated heuristically: In the derivation of (3), the term (푁 − 2)∕(푁 − 2 − 푐)
is dropped. Although the impact on the results is most likely negligible for moderate to large sample sizes, it could be sensible
to do a corresponding post-hoc adjustment of the approximate sample size푁퐴. It should be noted, however, that in general the
factor (푁퐴 −2)∕(푁퐴 − 2− 푐) is not equal to (푁 −2)∕(푁 −2− 푐), because푁퐴 is not necessarily equal to푁 . Moreover, the DF
adjustment is “stronger” than the GS adjustment for 푐 ≥ 2 and typical choices of 훼, because
푁퐷퐹 = 푁퐴 + 푐 +
푐2 + 2푐
푁퐴 − 2 − 푐
.
For example, for 훼 = 0.05 we have
푧2
1−훼∕2
∕2 ≈ 1.921 < 2 ≤ 푐
for 푐 ≥ 2. It can also be seen from the previous calculations that the difference might actually be small in most practically
relevant settings, especially as upward rounding has to be taken into account, too. Therefore, it could be sensible to apply an even
stronger adjustment of 푁퐴 by combining GS and DF, as proposed in (6). Anyway, a common feature of (5) and (6) is that, in
contrast to the GS adjustment, the number of covariates is taken into account. It has been argued that one of the major drawbacks
of using (3) or (4) was that the number of covariates did not play a role.17 Therefore, it seems plausible that the performance
can be improved by applying adjustments, which take the number of covariates 푐 into account.
Conflict of interest
The authors declare no potential conflict of interests.
SUPPORTING INFORMATION
The following supporting information is available as part of the online article:
SSRE_multiple_Ancova.R This file contains the implementation of the proposed re-calculation procedure (including a check
of initially specified parameters) in R.
SSRE_multiple_Ancova_Supplement.pdf This document contains simulation results for the fixed sample size calculation
settings discussed in the manuscript.
References
1. Huitema BE. The Analysis of Covariance and Alternatives: Statistical Methods for Experiments, Quasi-Experiments, and
Single-Case Studies. New York: Wiley; 2011. ISBN 9781118067468.
2. Frison L, Pocock SJ. Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for
design. Stat Med. 1992;11(13):1685–1704.
ZIMMERMANN ET AL 13
3. EMA . Guideline on adjustment for baseline covariates in clinical trials EMA/CHMP/295050/2013. 2015.
4. Sugiyama H, Uemura O, Mori T, Okisio N, Unai K, Liu M. Effect of imidafenacin on the urodynamic parameters of patients
with indwelling bladder catheters due to spinal cord injury. Spinal Cord. 2017;55:187–191.
5. Schönenberger S, Uhlmann L, Hacke W, et al. Effect of conscious sedation vs general anesthesia on early neurological
improvement among patients with ischemic stroke undergoing endovascular thrombectomy: A randomized clinical trial.
JAMA. 2016;316(19):1986–1996.
6. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-
positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled,
multicentre study. Lancet Neurol. 2017;16(12):976–986.
7. Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy
in adults with uncontrolled partial-onset seizures. Epilepsia. 2017;58(4):558–564.
8. Gholizadeh SS, Dehgan P, Mohammad-Alizadeh S, Aliasgarzadeh A, Mirghafourvand M. The effect of resistant dextrin
as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized,
triple-blind, controlled, clinical trial. Eur J Nutr. 2018;. accepted.
9. Haider S, Grabovac I, Winzer E, et al. Change in inflammatory parameters in prefrail and frail persons obtain-
ing physical training and nutritional support provided by lay volunteers: A randomized controlled trial. PLoS One.
2017;12(10):e0185879.
10. ICH . ICH Harmonized tripartite guideline: Statistical principles for clinical trials E9, step 4. 1998.
11. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting
parallel group randomised trials. BMJ. 2010;340:c869.
12. Dasgupta A, Zhang S, Thabane L, Nair P. Sample sizes for clinical trials using sputum eosinophils as a primary outcome.
Eur Respir J. 2013;42(4):1003–1011.
13. Teerenstra S, Eldridge S, Graff M, Hoop E, Borm GF. A simple sample size formula for analysis of covariance in cluster
randomized trials. Stat Med. 2012;31(20):2169–2178.
14. Borm GF, Fransen J, Lemmens W. A simple sample size formula for analysis of covariance in randomized clinical trials. J
Clin Epidemiol. 2007;60(12):1234–1238.
15. Guenther WC. Sample Size Formulas for Normal Theory T Tests. Am Stat. 1981;35(4):243–244.
16. Schouten HJA. Sample size formula with a continuous outcome for unequal group sizes and unequal variances. Stat Med.
1999;18(1):87–91.
17. Shieh G. Power and Sample Size Calculations for Contrast Analysis in ANCOVA.Multivariate Behav Res. 2017;52(1):1–11.
18. Tang Y. Exact and approximate power and sample size calculations for analysis of covariance in randomized clinical trials
with or without stratification. Stat Biopharm Res. 2018;. accepted.
19. Chi YY, Glueck DH, Muller KE. Power and Sample Size for Fixed-Effects Inference in Reversible Linear Mixed Models.
Am Stat. 2018;. accepted.
20. Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years of confirmatory adaptive designs: opportunities and
pitfalls. Stat Med. 2015;35:325–347.
21. Wassmer G, Brannath W. Group Sequential and Confirmatory Adaptive Designs in Clinical Trials. Switzerland: Springer;
2016.
22. Proschan MA. Two-Stage Sample Size Re-Estimation Based on a Nuisance Parameter: A Review. J Biopharm Stat.
2005;15(4):559–574.
14 ZIMMERMANN ET AL
23. Friede T, Kieser M. Sample Size Recalculation in Internal Pilot Study Designs: A Review. Biom J. 2006;48(4):537–555.
24. Friede T, Kieser M. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
Pharm Stat. 2011;10:8–13.
25. Friede T, Kieser M. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in
variance estimation. Pharm Stat. 2013;12(3):141–146.
26. Ravishanker N, Dey DK. A First Course In Linear Model Theory. New York: Chapman & Hall/CRC; 2002.
27. Schönenberger S, Möhlenbruch M, Pfaff J, et al. Sedation vs. Intubation for Endovascular Stroke TreAtment (SIESTA) – a
randomized monocentric trial. Int J Stroke. 2015;10(6):969–978.
28. Sullivan LM, D’Agostino RB. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in
randomized controlled trials. Stat Med. 2003;22:1317–1334.
29. Bathke AC, Brunner E. A Nonparametric Alternative to Analysis of Covariance. In: Akritas MG, Politis DN, eds. Recent
Advances and Trends in Nonparametric Statistics, Amsterdam: JAI 2003 (pp. 109–120).
30. Noether GE. Sample Size Determination for Some Common Nonparametric Tests. J Am Stat Assoc. 1987;85:645–647.
31. Govindarajulu Z. Sample Size Re-Estimation: Nonparametric Approach. J Stat Theory Pract. 2007;1(2):253–264.
32. EMA . Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design
CHMP/EWP/2459/02. 2007.
33. FDA . Adaptive Designs for Medical Device Clinical Studies (Draft Guidance). 2016.
